-
New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillationDaiichi Sankyo2021-04-26 09:44:48New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with
-
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCERDaiichi Sankyo2021-04-20 08:41:52ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2
-
Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCTDaiichi Sankyo2021-04-09 09:03:00Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCT
-
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaDaiichi Sankyo2021-04-07 09:27:33Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia
-
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal CancerDaiichi Sankyo2021-04-06 09:43:21DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal
-
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2021-03-29 09:32:36DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell
-
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell LymphomaDaiichi Sankyo2021-02-24 08:52:39Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with
-
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&DDaiichi Sankyo2021-02-22 13:14:52Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
-
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLCDaiichi Sankyo2021-02-02 16:39:14HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with
-
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research InstituteDaiichi Sankyo2021-02-02 16:28:25Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute
